Drugs / SNP-ACTH (1-39)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05696613 | Mar 2023 → Apr 2027 expected | idiopathic membranous glomerulonephritis | Cerium Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Cerium Pharmaceuticals, Inc. | Regulatory Cerium Pharmaceuticals receives FDA Orphan Drug Designation for Corticotropin (ACTH) porcine (synthetic) for the treatment of Membranous Nephropathy ceriumpharma.com ↗
Cerium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for Corticotropin (ACTH) porcine (synthetic), otherwise referred to as SNP-ACTH (1-39) Gel. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Cerium Pharmaceuticals, Inc. | Cerium Pharmaceuticals receives FDA Orphan Drug Designation for Corticotropin (ACTH) porcine (synthetic) for the treatment of Membranous Nephropathy ceriumpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNP-ACTH (1-39) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05696613 ↗ |
| Route | Subcutaneous | “3mg SNP-ACTH Gel subcutaneous (sc) injection 3 times per week” NCT05696613 ↗ |